Skip to content

13F-HR filed by Aquilo Capital Management, LLC

Aquilo Capital Management, LLC filed this 13F-HR for the quarter ended 2019-12-31, filed 2020-02-14, with 12 holding rows worth $266,237,000.

Accession
0001591986-20-000007
Filed
2020-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2019

A holdings report, 12 entries on the cover page, a total value of $266,237,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $266,237,000 with VALUE read as thousands by filing date, 13F file number 028-18892. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPDR SER TR78464A870S&P BIOTECH1,250,000$118,888,000thousands by filing dateput
UNIQURE NVN90064101SHS396,899$28,442,000thousands by filing date
PROQR THERAPEUTICS NVN71542109SHS EURO1,922,570$19,053,000thousands by filing date
PIERIS PHARMACEUTICALS INC720795103COM4,966,820$17,769,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock1,166,736$15,296,000thousands by filing date
LAKEFRONT BIOTHERAPEUTICS NV36315X101SPON ADR71,967$14,885,000thousands by filing date
MERUS N VN5749R100COM1,038,746$14,626,000thousands by filing date
DICERNA PHARMACEUTICALS INC253031108COM614,436$13,536,000thousands by filing date
SPERO THERAPEUTICS INC84833T103COM1,154,356$11,099,000thousands by filing date
REGENXBIO INC75901B107COM268,778$11,012,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM72,273$1,414,000thousands by filing date
MORPHOSYS AG617760202ADR6,080$217,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001591986-20-000007this filing2020-02-14acceptance time not in the bulk data set